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Abstract
Background: Pathogen diagnostic assays based on polymerase chain reaction (PCR) technology provide high 
sensitivity and specificity. However, the design of these diagnostic assays is computationally intensive, requiring high-
throughput methods to identify unique PCR signatures in the presence of an ever increasing availability of sequenced 
genomes.
Results: We present the Tool for PCR Signature Identification (TOPSI), a high-performance computing pipeline for the 
design of PCR-based pathogen diagnostic assays. The TOPSI pipeline efficiently designs PCR signatures common to 
multiple bacterial genomes by obtaining the shared regions through pairwise alignments between the input 
genomes. TOPSI successfully designed PCR signatures common to 18 Staphylococcus aureus genomes in less than 14 
hours using 98 cores on a high-performance computing system.
Conclusions: TOPSI is a computationally efficient, fully integrated tool for high-throughput design of PCR signatures 
common to multiple bacterial genomes. TOPSI is freely available for download at http://www.bhsai.org/downloads/
topsi.tar.gz.
Background
Rapid and accurate identification of pathogens from envi-
ronmental and clinical samples is essential for effective
containment of infectious diseases. Sequence-based iden-
tification methods, such as DNA microarrays and poly-
merase chain reaction (PCR) assays, are effective tools for
pathogen diagnostics. Whereas PCR-based assays pro-
vide high specificity, microarray-based assays provide
high multiplexing capability, accommodating thousands
of oligonucleotide probes in a single diagnostic assay. The
importance and utility of sequence-based identification
methods have further increased in recent times due to
advances in DNA sequencing technology that have led to
the availability of a large number of pathogen genomes.
A variety of tools have been developed in the past few
years to facilitate the design of pathogen-based diagnostic
assays [1-10]. Notable among these are the whole-
genome based signature design tools KPATH [6], Insignia
[3,11], and TOFI [8]. Whereas KPATH designs signatures
for PCR-based diagnostic assays and TOFI designs signa-
tures for microarray-based assays, Insignia finds unique
sequence segments that can be used to design both PCR
and microarray signatures. While, among many features,
these tools have the capability to identify common signa-
tures shared by multiple target genomes, each has its own
limitations. For example, KPATH computes consensus
regions among the target genomes from their multiple
alignments. However, multiple alignment of whole bacte-
rial genomes is computationally intensive and it is not
practical when a large number (> 20) of genomes is to be
analyzed. Conversely, TOFI and Insignia build consensus
regions among multiple genomes through pairwise align-
ments between the target genomes. Insignia server
reports only the unique segments in the target genomes
and provides an option for users to run the Primer3 [12]
PCR signature design software on these unique segments.
Manual manipulation is necessary to extract the PCR sig-
natures from Primer3 outputs and to perform further
specificity analysis on the extracted signatures. Further
manual manipulation is necessary when the unique seg-
m e n t s  r e p o r t e d  b y  I n s i g n i a  a r e  n o t  l o n g  e n o u g h  t o
accommodate a complete PCR signature, in which case
PCR signature components have to be designed individu-
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ally from smaller unique segments close to each other ,
and the individual components have to be manually
assembled to form valid PCR signatures. Insignia is
extremely fast, as it precomputes the matches between all
pairs of sequences. However, this advantage in speed
comes with a limitation; the user is restricted to genomic
sequences that are part of the Insignia database, and does
not possess an option to use other sequences as targets or
non-targets. The TOFI pipeline is free of most of the lim-
itations described above, but can only design signatures
for microarray-based diagnostic assays.
In this paper, we describe the T ool for PCR Signature
Identification (TOPSI), which extends the TOFI frame-
work [7-9] to design signatures for real-time PCR-based
diagnostic assays. Like Insignia, TOPSI uses pairwise
alignments to identify sequences that are common to
multiple genomes, and compares these sequences with
non-target genomes to identify unique segments suitable
for designing signatures. However, TOPSI goes beyond
the identification of unique segments, and incorporates
modules to design PCR signatures from the unique seg-
ments and perform extensive specificity analysis on the
designed signatures. Being fully integrated and auto-
mated, TOPSI takes a set of input target sequences and
provides a list of PCR signatures common to all input tar-
gets without the need for manual intervention in any of
the intermediate steps. Unlike existing software systems
for real-time PCR signature design, TOPSI is the only one
that is: freely available, high-throughput, and fully inte-
grated. The following are some of the unique features of
TOPSI:
• Highly scalable: TOPSI is very efficient and scalable, 
as a result of using pairwise alignments as opposed to 
multiple genome alignments.
• Fully integrated and automated: Complete PCR sig-
nature design and comprehensive specificity analysis 
are an integral part of TOPSI. PCR primers and 
probes are directly provided to the user, without the 
necessity for any manual manipulation.
• Freely available: TOPSI is freely available for down-
load and installation, giving users complete control 
over the selection of non-target databases and ensur-
ing user confidentiality of the applications.
The TOPSI pipeline has been primarily designed to
work with a large number of bacterial genomes. Design-
ing common signatures for multiple viral genomes offers
a different set of computational challenges. Although
viral genomes are much smaller in size, signature design
is complicated by the high variability within such
genomes and the consequent lack of conserved regions
suitable for signature design. As a result, the current
TOPSI framework might not be successful in designing
signatures common to a large number of viral genomes.
Implementation
A real-time PCR signature consists of two primers and a
probe, as shown in Figure 1. The two primers facilitate
PCR amplification of the target sequence, whereas the
probe serves to report the amplified product. The lengths
and thermodynamic properties of the three components
vary across different real-time PCR technologies.
Although the default parameters in the TOPSI pipeline
have been selected to be compatible with the T aqMan ®
real-time PCR system, TOPSI allows the user to custom-
ize all Primer3 input parameters, thereby enabling the
user to design signatures for any PCR platform for which
Primer3 can design signatures.
Overview of the pipeline
In the following, we briefly describe the TOPSI pipeline
for real-time PCR signature design. The TOPSI pipeline
consists of a pre-processing step, a post-processing step,
and three main stages as shown in Figure 2. Similar to the
previously developed TOFI pipeline [7-9], the different
stages are designed so that large portions of the target
genomes are eliminated in the less-expensive initial
stages, and the computationally expensive specificity
analysis is performed over smaller regions of the target
genomes in the third stage of TOPSI. All three stages of
Figure 1 Components of a real-time PCR signature. A real-time PCR signature consists of a forward primer, a probe, and a reverse primer. The 
lengths of these three components, the distances between them, and the total amplicon length can vary greatly depending on the real-time PCR 
technology. The values shown in the figure are typical for the TaqMan® real-time PCR assays.
Forward primer: 18-25 bp  Probe: 20-28 bp 
Reverse primer: 18-25 bp 
Amplicon length:  70-600 bp 
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the core TOPSI pipeline are executed in parallel on multi-
ple processors.
The input genomes are first compared with each other
using the suffix-tree-based MUMmer [13] program in the
pre-processing stage of TOPSI. Starting with an arbitrary
pair of input genomes, pairwise local alignment is per-
formed between the two genomes, and a list of conserved
sequence segments that are shared between the two
Figure 2 Overview of the TOPSI pipeline. The pre-processing stage of TOPSI obtains consensus sequence segments that are common to all input 
genomes. The actual signature design process, including comparison with non-target genomes, is performed in the three stages of the core TOPSI 
pipeline. The post-processing module assembles individual unique primers and probes into PCR signatures.
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Target genomes
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genomes is constructed from the pairwise alignment.
This list of conserved sequence segments is then sequen-
t i a l l y  c o m p a r e d  w i t h  e a c h  o f  t h e  r e m a i n i n g  i n p u t
genomes and continually updated so as to contain only
those sequence segments that are shared among all the
input genomes. Designing PCR signatures from these
conserved sequence segments ensures that each of the
input genomes is amplified by the designed signatures.
The first stage of the core TOPSI pipeline uses the
MUMmer program to perform pairwise comparison of
the conserved target sequences with each non-target
genome. This step eliminates any segments in the input
sequences that have exact matches longer than a user-
specified length with any of the non-target genomes in a
comprehensive sequence database, such as the nt data-
base provided by the National Center for Biotechnology
Information (NCBI). The surviving segments, referred to
as the candidate sequences, are then passed on to the sec-
ond stage of the pipeline.
In the second stage, TOPSI uses the open source
Primer3 [12] software to identify primers and probes
with the desired thermodynamic properties from the
candidate sequences. At this stage of the pipeline, for-
ward primers, reverse primers, and probes are designed
independently, without taking into consideration the dis-
tance constraints between the primers and probes. This
approach ensures that all unique primers and probes are
reported, which can later be used to design PCR signa-
tures in which only one, two or all three of the compo-
nents are unique.
The third stage of TOPSI performs specificity analysis
by performing BLAST [14] alignments of each primer
and probe with any comprehensive sequence database
provided by the user, such as the nt database. The BLAST
alignments are performed in parallel on multiple proces-
sors using the blastn program of the parallel BLAST
implementation mpiBLAST [15]. Based on the BLAST
alignments, primers and probes with significant align-
ments to non-target genomes are eliminated. The output
of this stage consists of individual primers and probes
that are unique to the target genome(s).
In the final post-processing step, the individual unique
PCR primers and probes are assembled into PCR signa-
tures by taking distance constraints into consideration.
First, PCR signatures with all three unique components
are identified. Further, PCR signatures with one or two
unique components are also designed by taking each
unique PCR primer or probe and designing non-unique
components by running Primer3 on the conserved target
sequence segments on either side of the unique compo-
nents. These PCR signatures with one or two unique
components are useful when there are very few or no
PCR signatures with all three unique components.
Criteria for specificity analysis
TOPSI uses a combination of multiple criteria for per-
forming specificity analysis, similar to TOFI [9]. These
criteria include the maximum percentage identity, the
longest stretch of contiguous/near-contiguous matches,
and the minimum number of mismatches with a non-tar-
get sequence. All these different criteria are evaluated
based on the BLAST alignments obtained with non-tar-
get sequences. Whereas thresholds on the maximum per-
centage identity and the longest stretch of contiguous or
near-contiguous matches are useful in evaluating the
specificity of longer sequences, thresholds for the mini-
mum number of mismatches with non-target sequences
are useful in evaluating the specificity of short primer or
probe sequences. Combining these criteria ensures that
probes and primers of all different lengths are specific to
the target genomes.
Signature ranking
To enable the user to select a subset of the in silico
designed PCR signatures, TOPSI assigns two different
scores to each PCR signature. The first score, called
uniqueness penalty, is a measure of the specificity of the
PCR signature. The uniqueness penalty of each compo-
nent of the PCR signature is calculated based on the best
non-target match and the length of the longest contigu-
ous match with a non-target sequence. A primer or probe
with overall identity or the longest contiguous match
exceeding pre-specified thresholds supplied by the user is
assigned a penalty score of 1. Conversely, a primer or
probe with no significant matches with non-target
sequences is assigned a uniqueness penalty of zero. The
uniqueness penalty for a PCR signature is computed as
the sum of the uniqueness penalties of the individual
components. The second score computed by TOPSI is
the sum of the penalty scores reported by Primer3 for
each of the three components, and is a measure of how
close the thermodynamic properties of these components
are to the optimal parameters selected by the user. The
user can select a subset of the PCR signatures by ranking
the probes based on any one of these scores, or by using a
combined score calculated by assigning customized
weights to each of the two scores.
Results
In this section, we report signatures designed by TOPSI
and compare them with those designed by other software
systems as well as some experimentally verified signa-
tures. We also discuss potential limitations of TOPSI.
Performance of the TOPSI pipeline
To evaluate the performance of TOPSI on a large set of
genomes, we ran TOPSI for a set of 18 Staphylococcus
aureus genomes using 98 cores of a Linux cluster withVijaya Satya et al. BMC Bioinformatics 2010, 11:340
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distributed memory. Table 1 shows the details of the 18 S.
aureus  genomes used. The combined size of these 18
genomes was greater than 50 Mbp. We used the NCBI nt
database (size ~30 Gbp) as the non-target sequence data-
base. The pre-processing step was very efficient, and
obtained consensus sequence segments shared among all
the 18 genomes in less than 10 minutes. Stage 1 and Stage
2 of the core TOPSI pipeline were also very fast, and fin-
ished within 50 and 15 minutes, respectively. As
expected, Stage 3 was the most computationally intensive
part of TOPSI. For this instance, Stage 3 of the TOPSI
pipeline took nearly 12 hours. The total execution time of
the pipeline was approximately 13.5 hours, illustrating
that TOPSI is extremely efficient in designing PCR signa-
tures for a large number of genomes.
Comparison with other software systems
T o evaluate the PCR signatures designed by TOPSI, we
compared them with signatures obtained from KP A TH
[6]. The developers of KPATH provided us with 1236
KPATH signatures for the 18 S. aureus genomes listed in
Table 1. We obtained 719 PCR signatures by running
TOPSI with the strict specificity thresholds listed in Table
2 .  B y  u s i n g  t h e  r e l ax ed  t h r e s h o l ds  l i s t ed  i n  T a b l e  2  t o
effectively eliminate some specificity criteria, we
obtained 2430 signatures. This indicates that the number
of signatures reported by TOPSI is comparable to that
obtained by KPATH. In total, there are 830 TOPSI signa-
tures that overlap with the KPATH signatures. It is
important to note that a direct mapping of TOPSI to
KPATH signatures is not possible because very few signa-
tures will be exactly the same in the two software systems.
This is due to small differences in the primer/probe
design criteria and in the input processing that lead to the
selection of a different set of PCR primers or probes in
the same region.
Figure 3 shows the distribution of TOPSI and KPATH
signatures in the S. aureus Mu50 genome. It can be seen
that both the TOPSI and the KPATH signatures are dis-
tributed throughout the genome. In the regions where
TOPSI does not report any signature, KPATH also does
not report any signature, indicating that these regions are
not suitable for designing unique PCR signatures. These
results provide semi-quantitative validation that the
number of signatures reported by TOPSI is similar to that
reported by KPATH, and that the TOPSI signatures are
distributed throughout the genome without the conspic-
uous omission of any region for which PCR signatures
have been reported by KPATH.
We attempted to obtain Insignia signatures using a total
of 21 S. aureus genomes that were accessible through the
Insignia Web server as of 4 June 2010, selecting the
option to include NCBI RefSeq among non-targets and
using a signature word length of 18 to match the corre-
sponding parameter in TOPSI. Insignia produced a set of
68,879 signature chains (i.e., candidate regions for signa-
Table 1: List of S. aureus genomes used for comparing TOPSI and KPATH
Strain Source NCBI Taxon ID
S. aureus subsp. aureus Mu50 Refseq:NC_002758 158878
S. aureus subsp. aureus COL Refseq:NC_002951 93062
S. aureus subsp. aureus JH1 Refseq:NC_009632 359787
S. aureus subsp. aureus JH9 Refseq:NC_009487 359786
S. aureus subsp. aureus MRSA252 Refseq:NC_002952 282458
S. aureus subsp. aureus MSSA476 Refseq:NC_002953 282459
S. aureus subsp. aureus Mu3 Refseq:NC_009782 418127
S. aureus subsp. aureus MW2 Refseq:NC_003923 196620
S. aureus subsp. aureus N315 Refseq:NC_002745 158879
S. aureus subsp. aureus NCTC 8325 Refseq:NC_007795 93061
S. aureus subsp. aureus str. Newman Refseq:NC_009641 426430
S. aureus RF122 Refseq:NC_007622 273036
S. aureus subsp. aureus USA300 FPR3757 Refseq:NC_007793 451515
S. aureus subsp. aureus USA300 TCH1516 Refseq:NC_010079 451156
S. aureus EMRSA15 draft sequence Sanger Institute N/A
S. aureus 0582 draft sequence Sanger Institute N/A
S. aureus subsp. aureus str. JKD6008 Refseq:NZ_ABRZ00000000 546342
S. aureus subsp. aureus str. JKD6009 Refseq:NZ_ABSA00000000 546343Vijaya Satya et al. BMC Bioinformatics 2010, 11:340
http://www.biomedcentral.com/1471-2105/11/340
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ture design) in less than a minute. As these signatures
were too many for the Insignia Web server to run
Primer3 or BLAST, we used the length filter to obtain
1,702 signature chains with length ≥ 28 bp. However, run-
ning Primer3 using the default parameters did not pro-
duce any PCR primers or probes, as the signature chains
were not long enough (each was ≤ 51 bp) to accommo-
date all three PCR components. Individual PCR compo-
nents could be designed independently, but Insignia does
not provide any module to assemble adjacent PCR com-
ponents into complete PCR signatures. Given that there
were thousands of signature candidates, it was impracti-
cal to assemble the PCR components manually for the
entire genome. To estimate the time necessary for speci-
ficity analysis, we used the BLAST search option in Insig-
nia to submit 400 signature chains to the NCBI BLAST
Web server, which took 1 hr and 26 minutes to produce
the results. Assuming that the average time per query
remains the same, it would take ~10 days to perform the
BLAST analysis on the original 68,879 signature chains
returned by Insignia. These results suggest that although
Insignia might be extremely useful and convenient for
designing a few signatures from selected regions of the
target genome, unlike TOPSI, it is not ideal for high-
Table 2: Specificity thresholds used in TOPSI runs for S. aureus
Specificity parameter Strict threshold Relaxed threshold
M0 - longest stretch of contiguous matches with a non-target that has no mismatches 18 18
M1 - longest stretch of contiguous matches with a non-target that has at most one mismatch 20 40
M2 - longest stretch of contiguous matches with a non-target that has at most two mismatches 22 40
M3 - longest stretch of contiguous matches with a non-target that has at most three mismatches 24 40
Maximum overall identity with a non-target sequence 90% 90%
Figure 3 Distribution of TOPSI and KPATH signatures in the S. aureus Mu50 genome. The distributions shown here are for the 1236 KPATH sig-
natures and the 2430 TOPSI signatures obtained using relaxed thresholds. Both TOPSI and KPATH signatures are distributed throughout the S. aureus 
genome. The regions in which there are very few or no TOPSI signatures also have very few or no KPATH signatures, indicating that these regions are 
in fact not suitable for PCR signature design.
 Vijaya Satya et al. BMC Bioinformatics 2010, 11:340
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throughput, whole-genome signature design on bacterial
genomes that might result in thousands of signature can-
didates.
Comparison with experimentally verified signatures
To compare TOPSI signatures with experimentally veri-
fied signatures, we selected the extremely difficult case of
PCR signatures that are unique to Burkholderia mallei
with respect to Burkholderia pseudomallei. B. mallei and
B. pseudomallei are closely related pathogens that cause
different diseases, glanders and melioidosis, respectively
[16]. B. mallei is believed to have been clonally evolved
from B. pseudomallei [17], with a significantly reduced
genome due to the loss of genes. Due to the similarity of
B. mallei with respect to B. pseudomallei, a literature
search revealed only one PCR signature that was reported
to be unique to B. mallei [16]. However, both primers in
this signature (5'-TTCGATCGATTCCTGCTATC-3' and
5'-GCGTTAAACGCCGTACTTTC-3') have exact
matches with some newly sequenced B. pseudomallei
strains. The Web-based tool Primer-BLAST http://
www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi pre-
dicts that these primers will amplify B. pseudomallei
strains 33, 172, 491, and 668. Hence, this PCR signature
can no longer be considered to be unique to B. mallei.
Another set of 10 experimentally validated B. mallei
specific PCR signatures were available from the Center
for Bioinformatics and Computational Biology at the Uni-
versity of Maryland http://insignia.cbcb.umd.edu/pdf/
burkholderia.pdf. These real-time PCR signatures were
designed through their Insignia [3] system. However,
BLAST comparisons of the primers and probes compris-
ing these signatures with the NCBI whole-genome shot-
gun sequence (WGS) database in October 2009 revealed
that five of these signatures did not meet our design crite-
ria. Reasons for eliminating these signatures are listed in
Additional file 1. The remaining five PCR signatures were
still unique to B. mallei sequences.
We ran TOPSI with 11 B. mallei genomes shown as tar-
gets, using a non-target database which included the
NCBI nt database and 23 B. pseudomallei genomes. Table
3 shows the 11 B. mallei genomes used. With these
inputs, TOPSI designed 11 real-time PCR signatures in
which all three components were unique to and present
in all the 11 B. mallei genomes. However, seven out of
these 11 signatures were eliminated when compared
against the WGS database, due to matches with draft
non-target genomes. Table 4 shows the remaining four
TOPSI signatures. Figure 4 shows the relative positions of
these four TOPSI signatures and the five experimentally
verified signatures from the University of Maryland
(described above). It can be seen that three of the four
TOPSI signatures are within 300 bp of one of the five
experimentally verified signatures. This indicates that
TOPSI was successful in identifying the experimentally
verified unique regions of B. mallei. One TOPSI signature
and one experimentally verified signature do not have any
counterparts in their immediate neighborhoods.
Figure 4 Comparison of TOPSI signatures with experimentally verified signatures for B. mallei. The four TOPSI signatures and five experimen-
tally verified signatures provided by the University of Maryland are mapped to the B. mallei ATCC 23344 genome.
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Potential limitations of TOPSI
One potential limitation of TOPSI, and of other similar
high-throughput signature design software systems, is
their difficulty in designing signatures for viral genomes,
as described by Philippy et al.[3]. Because of their small
genomes and high variability, it may not be possible to
find conserved segments to design signatures from. We
tested TOPSI with two viral agents, Variola major and
human adenovirus. TOPSI identified six in silico PCR sig-
natures (with at least one unique segment) common to 40
Variola major genomes, using three Variola minor
genomes as non-targets, based on the classification pro-
vided by Esposito et al. [18]. In contrast, TOPSI could not
identify any common signatures for 16 human adenovirus
genomes consisting of subgroups A, B, C, D, E and F.
However, TOPSI could design unique PCR signatures
common to two genomes of human adenovirus subgroup
D. Our experience based on this limited testing with viral
genomes indicates that it might be possible for TOPSI to
design common signatures for large DNA viruses. How-
ever, TOPSI might not be able to design common signa-
tures for short RNA viruses, in which case methods
specifically designed for viral genomes, such as the one
described by Duitama et al. [19], need to be incorporated.
Another issue of concern is the effect of draft or incom-
plete genomes on signature design. In the current TOPSI
framework, PCR signatures are designed from genomic
regions that are conserved among all the input genomes.
This might potentially lead to a situation in which signa-
tures common to a large number of input genomes are
eliminated because of a single low-quality or incomplete
genome sequence. One possible solution for this problem
is to apply a lower threshold for consensus, so that signa-
tures can be designed from regions that are conserved
among a large percentage of the input genomes. This
approach is compatible with the current TOPSI frame-
work and could be incorporated into the system. How-
ever , this solution would lead to signatures that do not
identify some of the target genomes. Therefore, it should
be used only when signatures common to all targets can-
not be identified. Another solution using the current
TOPSI framework is to design signatures based solely on
Table 3: List of 11 B. mallei genomes used for designing common signatures
Strain Source NCBI Taxon ID
B. mallei ATCC 23344 Refseq:NC_006348, Refseq:NC_006349 243160
B. mallei NCTC 10229 Refseq:NC_008836, Refseq:NC_008835 412022
B. mallei NCTC 10247 Refseq:NC_009080, Refseq:NC_009079 320389
B. mallei SAVP1 Refseq:NC_008785, Refseq:NC_008784 320288
B. mallei PRL-20 JCVI 436115
B. mallei PRL7 JCVI 536228
B. mallei 2002721280 JCVI 370895
B. mallei ATCC 10399 JCVI 412021
B. mallei FMH JCVI 334802
B. mallei GB8 horse 4 JCVI 320390
B. mallei JHU JCVI 334803
Table 4: TOPSI signatures for B. mallei. 
Chr. Forward primer
(position)
Probe
(position)
Reverse primer
(position)
Amplicon length
1 ACTGCTGTACCGCGCTCTTT
(2632348)
ATTCGCAGCACCCATTACAACCGTTG 
(2632376)
GCTGAAGAGTGGCTGCAATG
(2632449)
121
1 GGTCTACAGCTCCGCGAATT
(3187456)
CTCAAACCGTTAGGCGACTCAAGGTGC
(3187488)
ATGGCATGGTGCTGTGAAAC
(3187528)
92
2 CGAGCCATCGACCTCATG 
(1094082)
ACATGTCGAAGCATTTTTCGCCGC
(1094188)
TCGGCGATCGATGGTCTAG
(1094228)
165
2 CTCCCACGCCGACTGATAC
(1094844)
AAGCTGTTGATCGTGCAACACCAGCAC
(1094883)
CGGTGAAACCTGGATACTGGA
(1094938)
115
The positions and amplicon lengths are with reference to the B. mallei ATCC 23344 genome.Vijaya Satya et al. BMC Bioinformatics 2010, 11:340
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finished genomes as a first step, and subsequently filter
the obtained signatures by applying a threshold on the
percentage of draft (or incomplete) genomes that are
identified by each signature. Alternatively, if sequence
quality scores are available, taking them into consider-
ation while evaluating the consensus regions might also
lead to identifying signatures that might otherwise be
eliminated.
Conclusions
The TOPSI pipeline is efficient in designing real-time
PCR signatures that are common to multiple strains of a
bacterial pathogen, and are also unique to the pathogen
with respect to all other sequenced non-target genomes.
Comparison with PCR signatures designed using a well-
established software system shows that the TOPSI signa-
tures are similar to those designed by the other software,
and comparison with experimentally verified signatures
shows that TOPSI is able to report signatures from
unique regions of the pathogen genome. Being the only
freely available, high-throughput, and fully integrated
solution for the design of real-time PCR signatures,
TOPSI provides a valuable contribution to the develop-
ment of pathogen diagnostic assays.
Availability and requirements
• Project name: TOPSI
• Project home page: http://www.bhsai.org/down-
loads/topsi.tar.gz
• Operating systems: Linux
• Programming language: Perl
• Other requirements: mpiBLAST 1.4.0 or later, 
MUMmer 3.19 or later, Primer3 1.1.4 or later, BioPerl, 
and a Linux cluster with PBS queuing system
TOPSI is also operational as a Web server at a U.S. 
Department of Defense (DoD) high-performance 
computing center. Sponsorship for access to these 
resources may be requested by contacting the corre-
sponding author.
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